ePRO: A Maturing and Widely-Preferred Market
Industry Standard Research
The adoption of technologies is generally increasing throughout clinical trials. It took the industry some time to fully adopt and integrate EDC as the de facto standard for data collection but that has happened. ISR's data show EDC is now the data collection method of choice for the vast majority of clinical trials. We're also witnessing the maturation of other technologies in clinical trials such as online dashboards that aggregate clinical trial metrics and report on study progress; we see clinical sites relying more heavily on their electronic medical records for feasibility and patient recruitment; and we find clinical investigators and study coordinators prefer electronic patient reported outcomes (ePRO) over paper PRO.
The stage is set for further proliferation of not only ePRO, but a much broader set of eClinical service offerings and value propositions. Service providers, technology developers, and CROs need to know where their products stand and sponsors should be aware of how their partners are viewed by one of the most important cogs in the clinical development wheel: the investigative sites.
—Industry Standard Research, www.ISRreports.com/.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
